Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry
This article was originally published in The Pink Sheet Daily
One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.
You may also be interested in...
European Notebook: Revolutionary Change Needed for European Biotech; CHMP Releases Opinions Agenda; Growing Interest In Biosimilars
Radical change urged to help Europe compete in biotech; CHMP becomes less secretive over its meeting agendas; Almirall restructures its European business and buys U.S. dermatology business; biosimilar biologics companies, Almotech and Samsung Bioepis, target Europe.
The new European biotech aims to become a profitable niche player focused on anti-infective vaccines and antibodies in 2015.
The week before Christmas proved to be an extraordinarily busy one for biopharmaceutical business development, highlighted by a Pfizer deal to enhance delivery of its biologics, an ALS research consortium led by Biogen Idec and the merger of two European companies, creating vaccine- and antibody-focused Valneva.